DGAP-News

Sangui BioTech International Inc.: Revenues of USD 127,000 in financial year 2015; net loss, cash burn reduced; revenues from Granulox license fees in EUR up 34.4%

DGAP-News: Sangui BioTech International Inc. / Key word(s): Final
Results
Sangui BioTech International Inc.: Revenues of USD 127,000 in
financial year 2015; net loss, cash burn reduced; revenues from
Granulox license fees in EUR up 34.4%

29.09.2015 / 20:54

---------------------------------------------------------------------

SanguiBioTech: Revenues of USD 127,000 in financial year 2015; net loss,
cash burn reduced;revenues from Granulox license fees in EUR up 34.4%

Witten, Germany, September 29, 2015

For its financial year 2015 (ended June 30, 2015) Sangui BioTech
International, Inc. reports revenues from product sales and royalties in
the amount of USD127,469, a decrease of 4.5% as compared to the revenues in
the financial year 2014, which came in at USD133,470. Revenues in the
fourth quarter were recorded at USD10,909 (Q4/2014: USD43,729). The
decrease for the financial year and the quarter is due primarily to a sharp
decline in product sales. Royalties from the licensing agreement regarding
the wound treatment product Granulox engrossed by SanguiBioTech GmbH in the
operating currency EUR, however, increased by 34.4% in the 2015 financial
year. Granulox is the first dressing to significantly improve oxygen supply
to wounds with poor blood supply and thereby decisively accelerates wound
healing.

Research and development expenses decreased to USD204,987 (FY 2014:
USD543,071). The previous year position included the purchase of a
comprehensive set of clinical data. This decrease along with cost saving
efforts contributed to a significantly reduced net loss attributable to
shareholders in the amount of USD0.7 million (FY 2014: USD1.4 million).
Cash outflows from operations were also reduced and amounted to USD0.6
million (FY 2014: USD0.8 million). They were not fully offset by cash
inflows from financing and investing activities which amounted to USD0.5
million (FY 2014: USD0.7 million).

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

For more information please contact:

Joachim Fleing
Phone: [phone]
Fax: [phone]
e-mail: [e-mail]

Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other "forward-looking" information. These statements
are subject to known and unknown risks, uncertainties, and other factors
that could cause the actual results to differ materially from those
contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections include,
among many others, the ability of the Company to raise sufficient capital
to meet operating requirements. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," and variations of
such words and similar expressions are intended to identify such
forward-looking statements. Unless required by law, the Company undertakes
no obligation to update publicly any forward-looking statements, whether as
a result of new information, future events or otherwise.



---------------------------------------------------------------------

29.09.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


398201 29.09.2015